GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Posting this during a quiet moment, in the hope that it offers some tonic to the disingenuous lunacy one sees on this board daily from the same handful of posters.
I feel that a buy-out from a big pharma player is a strong possibility here, for obvious reasons others have articulated previously. What strikes me though is the feeling of deja-vu I'm experiencing, stemming from my experience of being a holder of a US stock a few years ago. At the time, it had a similar mcap to Angle and had developed a novel product and treatment pathway in the food allergy field. As its Phase III trial was concluding, it was bought out by a well-known, global confectionary maker, following three earlier (and relatively small) investments by them in the company over a period of a year or so.
It is my opinion - and hope - that this is what we're seeing here with AZ and that an offer will be made in due course.
Until this happens - and indeed, if it happens - all the best you all.
The Co's with the "insider information" on this are of course the big Pharma Co's and the Companies that do the Molecular analysis of DNA fragments found in the blood, so called CtDna analysis (the likes of Illumina and Thermo Fisher).
Both these industries must have a very good idea where Angle Plc's fortunes are heading over the next say ten years. I suspect they can now see that analysing the circulating tumour cells in cancer patients will increasingly be needed, and the "Companion diagnostic" that Mr Newland has mentioned is a real possibility. Those two points are financially massive.
More contracts with large Pharma Co's similar to the one with Eisai Inc. and the two with Astrazeneca are inevitable. Once this news flow is clearly established, I can easily see Angle Plc getting an offer. It's whether the likes of me will accept it. I'm not sure if I would accept 50p a share frankly.
All IMHO.
I’m not sure but it’ll be interesting to see how this develops, the science is very interesting and importantly working. I’m happy to hold these in any case.
Clearly the company is making great strides so ignoring the daily movements for now.
It occurs to me that IF analysing circulating tumour cells (live tumour cells like 99% of the ones Parsortix catches) during drug trials becomes the standard then any suitor will steal the march on their competitors. In fact the market would be cornered, would it not? Food for thought!
Al, firstly thank you for posting and the sentiment.
It seems to me AGL should be an attractive target for the obvious suitors and I hope it is.
But I hope more that I correctly remember AN saying that the big investors were in it for the long term and not after an exit at the first opportunity.
That is where the big multiples are and that's the outcome I'm after.
Ha, that's a good joke SLF - all the 'big' investors have jumped ship thanks to AN's incompetence - thank goodness the P system is top of its class, is all I can say (no thanks to him).
Carrot
Let other posters be clear. 99% of Parsortix tumour cells captured may be alive, but be under no illusion that Parsortix captures CTCs in every case of cancer, even where metastatic spread is evident. It simply does not, and that limits the value of the technique.
This is not de-ramping, as you would have it, but an ineluctable fact.
A potentially interesting observation Moab - but remember the test where just one cancer cell was deliberately added to the blood sample - and Parsortix captured it... ?
so I'm not sure what your agenda is...or is based upon...?
Researcher1 Parsortix is around 69% successfully in detecting cancer cells its the 31% failure rate to detect cancer cells I'm worried about!
That’s very very good at this stage.
Researcher 1, re yours of 17th May
I have no agenda, paranoia not helpful here. If a blood sample is spiked with a malignant cell, Parsortix will capture it, a doddle akin to shooting animals in a zoo. but as I and others have repeatedly pointed out, from a population of patients with metastatic malignancy, it is not possible to capture malignant cells from a single blood sample on 100% of patients; some will simply not have circulating tumour cells to capture at the time of sampling.
No agenda, just fact.